deltatrials
Completed PHASE2 NCT00004488

Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease

Sponsor: Children's Hospital Medical Center, Cincinnati

Conditions Gaucher's Disease Osteopenia
Interventions alendronate sodium calcium carbonate cholecalciferol
Updated 5 times since 2017 Last updated: Mar 24, 2015 Started: Oct 31, 1998 Completion: Sep 30, 2002

This PHASE2 trial investigates Gaucher's Disease and Osteopenia and is currently completed. Children's Hospital Medical Center, Cincinnati leads this study, which shows 5 recorded versions since 1998 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Oct 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Children's Hospital Medical Center, Cincinnati
Data source: FDA Office of Orphan Products Development

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Cincinnati, United States
  • • Dayton, United States
  • • Jerusalem, Israel